Canada’s Intellectual Property Firm

PMPRB January 2019 News

Authored byLynn Ing

PMPRB issues a Notice of Hearing for allegations of excessive pricing of PROCYSBI

The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.

News ReleaseNotice of HearingStatement of Allegations of Board Staff

Under reserve: Appeal from judicial review quashing PMPRB decision on jurisdiction over DIFFERIN

On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada’s appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma’s DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found  here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.